Biodexa Pharmaceuticals PLC, a clinical stage biopharmaceutical company, has announced that Health Canada has approved its Phase 2a study of tolimidone for Type 1 diabetes. The study, which is an Investigator Initiated Trial, will be conducted by the University of Alberta and will measure key markers such as C-peptide levels and HbA1c over a three-month period compared to baseline in 12 patients across three dose groups. The study may expand in the future, and the first patient enrollment is expected within the current quarter. Tolimidone, a drug initially developed by Pfizer for gastric ulcers but discontinued due to lack of efficacy, has been identified as a potential treatment for Type 1 diabetes following preclinical studies. Biodexa aims to build on the existing data...Show More

Biodexa Pharmaceuticals PLC, a clinical stage biopharmaceutical company, has announced that Health Canada has approved its Phase 2a study of tolimidone for Type 1 diabetes. The study, which is an Investigator Initiated Trial, will be conducted by the University of Alberta and will measure key markers such as C-peptide levels and HbA1c over a three-month period compared to baseline in 12 patients across three dose groups. The study may expand in the future, and the first patient enrollment is expected within the current quarter. Tolimidone, a drug initially developed by Pfizer for gastric ulcers but discontinued due to lack of efficacy, has been identified as a potential treatment for Type 1 diabetes following preclinical studies. Biodexa aims to build on the existing data and develop tolimidone for this new indication. The company's CEO and CFO, Stephen Stamp, expressed excitement about initiating the clinical program in collaboration with the University of Alberta. Biodexa's pipeline also includes eRapa™ for Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer, and MTX110 for rare/orphan brain cancer indications. The company is headquartered in Cardiff, UK, and focuses on developing innovative products for diseases with unmet medical needs.